

SUPPLEMENTAL DIGITAL CONTENT 3

Snapshot Analysis of Participants With HIV-1 RNA <50 Copies/mL at Week 96 in the ITT-E Population From GEMINI-1 and GEMINI-2

	GEMINI-1		GEMINI-2	
	2DR	3DR	2DR	3DR
Snapshot outcome, n (%)	(N=356)	(N=358)	(N=360)	(N=359)
HIV-1 RNA <50 copies/mL	300 (84.3)	320 (89.4)	316 (87.8)	322 (89.7)
HIV-1 RNA ≥50 copies/mL	11 (3.1)	5 (1.4)	11 (3.1)	9 (2.5)
Data in window and HIV-1 RNA ≥50 copies/mL	1 (0.3)	0	3 (0.8)	4 (1.1)
Discontinued for lack of efficacy	4 (1.1)	2 (0.6)	5 (1.4)	1 (0.3)
Discontinued for other reason and HIV-1 RNA ≥50 copies/mL	5 (1.4)	3 (0.8)	2 (0.6)	3 (0.8)
Change in ART	1 (0.3)	0	1 (0.3)	1 (0.3)
No virologic data at Week 96	45 (12.6)	33 (9.2)	33 (9.2)	28 (7.8)
Discontinued study because of AE or death	12 (3.4)	13 (3.6)	10 (2.8)	8 (2.2)
Discontinued study for other reasons	33 (9.3)	20 (5.6)	23 (6.4)	18 (5.0)
Withdrew consent	10 (2.8)	6 (1.7)	8 (2.2)	9 (2.5)
Lost to follow-up	10 (2.8)	6 (1.7)	8 (2.2)	4 (1.1)
Protocol deviation	6 (1.7)	5 (1.4)	4 (1.1)	3 (0.8)
Physician decision	7 (2.0)	3 (0.8)	3 (0.8)	1 (0.3)
Lack of efficacy	0	0	0	1 (0.3)
On study but missing data in window	0	0	0	2 (0.6)

AE, adverse event; ART, antiretroviral therapy; 2DR, 2-drug regimen (dolutegravir + lamivudine); 3DR, 3-drug regimen (dolutegravir + tenofovir disoproxil fumarate/emtricitabine); ITT-E, intention-to-treat–exposed.